Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension

Keyphrases

• Ocular Hypertension 100%
• Primary Open-angle Glaucoma 100%
• Netarsudil 100%
• Rho Kinase Inhibitor 100%
• Confidence Interval 70%
• Latanoprost 70%
• Monotherapy 58%
• Timolol 58%
• Combination Therapy 52%
• I(2) 35%
• Placebo 29%
• Intraocular Pressure 29%
• Glaucoma 23%
• Certainty of Evidence 23%
• Intraocular Pressure Reduction 23%
• Cochrane 17%
• Risk of Bias 17%
• Ripasudil 17%
• Non-associated 11%
• High Risk 11%
• Low Risk 11%
• Current Treatment 11%
• Beta-blockers 5%
• Etiology 5%
• Medical Treatment 5%
• Incidence Rate 5%
• Treatment Discontinuation 5%
• Meta-analysis 5%
• Multicenter Trial 5%
• Randomized Clinical Trial 5%
• Canada 5%
• Extracted Data 5%
• Prostaglandin Analogs 5%
• Long-term Safety 5%
• Japan 5%
• Retinal Ganglion Cells 5%
• Optic Neuropathy 5%
• Visual Field Defect 5%
• Axonal Loss 5%
• Pharmacodynamics 5%
• Pharmaceutical Companies 5%
• Long-term Efficacy 5%
• Commercially Available 5%
• Treatment Goals 5%
• Glaucoma Medication 5%
• Funding Sources 5%
• Trabecular Meshwork 5%
• Trial Duration 5%
• Methodological Procedures 5%
• Review Authors 5%
• Glaucoma Progression 5%
• Hypotensive Effect 5%
• Intraocular Pressure Measurement 5%
• Aqueous Humor 5%
• Schlemm's Canal 5%
• Irreversible Blindness 5%
• RoB 2 5%
• Low Intraocular Pressure 5%
• Primary Glaucoma 5%

Neuroscience

• Intraocular Pressure 100%
• Rho Kinase 100%
• Open-Angle Glaucoma 100%
• Latanoprost 100%
• Ocular Hypertension 100%
• Timolol 81%
• Glaucoma 63%
• Placebo 45%
• Meta-Analysis 9%
• Retinal Ganglion Cell 9%
• Optic Neuropathy 9%
• Visual Field Defect 9%
• Eye 9%
• Beta Blocker 9%
• Prostaglandin Analogue 9%
• Aqueous Humor 9%
• Trabecular Meshwork 9%
• Axonal Cell 9%
• Latanoprost Plus Timolol 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Rho Kinase Inhibitor 100%
• Intraocular Hypertension 100%
• Open Angle Glaucoma 100%
• Netarsudil 100%
• Latanoprost 64%
• Monotherapy 58%
• Combination Therapy 58%
• Timolol 52%
• Placebo 29%
• Glaucoma 29%
• Ripasudil 17%
• Beta Adrenergic Receptor Blocking Agent 5%
• Disease 5%
• Randomized Clinical Trial 5%
• Pharmacodynamics 5%
• Optic Nerve Disease 5%
• Prostaglandin Analogue 5%
• Glaucoma Medication 5%
• Visual Field Defect 5%
• Latanoprost Plus Timolol 5%
• Primary Glaucoma 5%